meta
|
evidence
oncology
Living systematic review and meta-analysis
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
2
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
5
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
Asian type
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (liver )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
deaths (OS)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
versus placebo
nivolumab alone vs. placebo
1
certainty unassessable
-15%
nivolumab plus ipilimumab vs. placebo
1
certainty unassessable
-7%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open